June 18, 2013
/PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) has priced its previously announced public offering of common shares (the "Offering"). Pursuant to the Offering, the Company will issue 23,529,412 common shares at a price of
per share, for aggregate gross proceeds of approximately
. The Company will file a final prospectus supplement to its effective shelf registration statement on Form S-3 and will make a similar filing with the securities regulatory authorities in each of the provinces of Canada. Closing of the Offering is expected to occur on or about
June 24, 2013
The Company has also granted to the underwriters of the Offering an option, exercisable for a period of 30 days following the date of the final prospectus supplement, to purchase additional common shares equal to up to 15% of the common shares initially sold.
The Company intends to use the net proceeds from the Offering, together with debt financing, to fund (i) the consideration of its previously disclosed acquisition (the "Merger") of Bausch + Lomb Holdings Incorporated ("B+L"), (ii) the fees and expenses incurred in connection with the Merger; and (iii) the repayment or retirement of B+L's outstanding debt. If the Merger were not to close for any reason, the proceeds of the Offering will be used for general corporate purposes, which may include providing working capital, funding capital expenditures or for making one or more future acquisitions.
Goldman, Sachs & Co. will act as sole manager of the Offering outside of
and Goldman Sachs Canada Inc. will act as sole manager of the Offering in Canada.
A copy of the final prospectus supplement and accompanying prospectus relating to the Offering in
the United States
(the "U.S. Prospectus") will be available on EDGAR at
and a copy of the final prospectus supplement and accompanying base shelf prospectus relating to the Offering in
(the "Canadian Prospectus") will be available on SEDAR at
. Alternatively, a copy of the U.S. Prospectus may be obtained from Goldman, Sachs & Co. at 200 West Street,
New York, New York
10282, Attn: Prospectus Department, telephone: 866-471-2526, facsimile: 212-902-9316, email:
and a copy of the Canadian Prospectus may be obtained from Goldman Sachs Canada Inc. at 77 King Street West, Suite 3400,
M5K 1B7, Attn: Prospectus Department, telephone: 866-471-2526, facsimile: 212-902-9316, email:
This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.